American Consumers Careful With Spending in Summer 2014

See on - Consumer Empowered Marketing

Most Americans are using cost-saving measures to purchase items this summer. A majority have recently bought generic goods and gone online to find the best deal, while fewer have gone shopping for fun or made major purchases.

See on

About 2 months ago I accidentally trashed my Trek Domane, which was my favorite bike, by driving into the garage with it mounted on my roof rack. After a short period of mourning I decided to get a replacement an opted for the Tek 5.0 Domane Red, 58cm. After one ride I could tell something was not right and decided to go to Landry’s bike store in Natick to have a custom fitting. After a number of adjustments and computer analysis Landry’s said it would be better for them to take the bike back and for me to get a custom Trek Project One Domane. After 3 rides so far it was well worth the wait.

DTC marketing is slow to change

DTC marketing is slow to change

dtcchangePOST SUMMARY: The news this week that more than half of all biopharma employees are looking to leave the industry should be a wake-up call for senior managers, but it may be too late as both digital and DTC pharma marketing continue to struggle to transform the organization from “big pharma” mindset to operating with a sense of urgency with a focus more on patients. (more…)

View On WordPress

Content, we all say that content is king, but do consumers really have the time to read all that content? Not according to a new survey from FleishmanHillard. The big takeaway here seems to be that coupons (76%) and promotions (59%) still rank highly in the hierarchy of information a company can provide.

Health apps and websites are no substitute for a visit to the doctor

Health apps and websites are no substitute for a visit to the doctor

healthappsAt its annual shindig in Chicago, physicians in the American Osteopathic Association over the weekend agreed to warn patients that health apps and websites are no substitute for a visit to the doctor. (more…)

View On WordPress

More than half pharma employes want to leave

More than half pharma employes want to leave

2014 engagementEmployees in the U.S. biotech and pharma industries express significant interest in accepting or seeking out a new employment offer, according to a new Randstad Pharma Engagement Study.  The study reveals that within the next six months one-half (51%) of biotech/pharma workers are likely to seek out a job in a different company or organization, as compared to 38 percent of all employees polled.…

View On WordPress

There is a lot of chatter how social media is no longer a wise decision for businesses to partake in. Some Brands dedicate a lot of time to social media but the return on investment just isn’t there. This certainly holds true for many B2B type businesses, but it is not the case when it comes to e-Commerce companies.

Is DTC marketing heading towards irrelevance ?

Is DTC marketing heading towards irrelevance ?

irrelevancePOST SUMMARY: Unless pharma marketers are willing to take risks and transform outdated business models and processes DTC marketing could be headed in the same direction as the dinosaur.    (more…)

View On WordPress

Great online brands combine ongoing testing, feedback and improvement cycles into their daily practices and invest in listening, learning and modifying the user experience to create positive returns in revenue and loyalty. This means user experience is not just a practice or a process—it is a philosophy.

Drug costs high but still better tan alternatives

Drug costs high but still better tan alternatives

drugcostsPOST SUMMARY: (via Boston Globe) Fewer than 4 percent of patients use specialty drugs, but they account for 25 percent of total drug spending.  “The impact of the specialty tier benefit design falls disproportionately on patients who are living with diseases and conditions that are serious and life-threatening,” said Marialanna Lee, Northeast Region state government affairs director for the…

View On WordPress

Tags: Drug costs